More Than 5,000 Lung Cancer Patients Treated With CyberKnife System to Date
SUNNYVALE, Calif., March 26 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that approximately 90 percent of CyberKnife centers worldwide are now treating lung cancer with the CyberKnife(R) Robotic Radiosurgery System*. The number of lung cancer patients is growing significantly as well, with more than 5,000 individuals receiving CyberKnife treatments to date.
Lung cancer deaths are predicted to increase dramatically, according to a recent report from the World Health Organization (WHO). Lung cancer is expected to become more prominent in the underdeveloped world as a result of an anticipated rise in the use of tobacco products, which is the primary cause of approximately 80 percent of all lung cancer. The WHO "Report On The Global Tobacco Epidemic" projects that lung cancer incidence will increase from 18 million cases in the 20th century to 180 million cases in the 21st century worldwide. The majority of lung cancer cases are expected to be concentrated in 10 countries: China (30 percent of all cases), India (10 percent), Indonesia, Russia, the United States, Japan, Brazil, Bangladesh, Germany and Turkey.
"CyberKnife represents an important advance in the treatment of lung cancer. The CyberKnife System's unparalleled accuracy allows me to offer an effective, non-invasive treatment option for patients with early-stage lung cancer who are not good candidates for surgery," Richard Whyte, M.D., professor of cardiothoracic surgery at Stanford University Medical Center.
In many cases, patients with lung cancer also suffer from other medical
conditions that could preclu
|SOURCE Accuray Incorporated|
Copyright©2008 PR Newswire.
All rights reserved